CCD 3693
Alternative Names: CO 32693Latest Information Update: 23 Dec 2002
At a glance
- Originator Purdue Pharma
- Class Sleep disorder therapies
- Mechanism of Action GABA A receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Insomnia
Most Recent Events
- 23 Dec 2002 Discontinued - Phase-I for Insomnia in Europe (unspecified route)
- 13 Aug 1998 Agreement between CoCensys and Searle to collaborate on development of CCD 3693 has been terminated
- 06 Mar 1998 Phase-I clinical trials for Insomnia in Europe (Unknown route)